Arrowhead has not initiated research coverage on Khiron Life Sciences Corp. yet.

About
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and...
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
  • 18
    Jul
    22
    News Release
    Khiron Appoints Helen Bellwood (ACA) as Interim CFO
  • 6
    Jul
    22
    News Release
    Medical Cannabis Leader Khiron Continues Global Expansion into Spain
  • 28
    Jun
    22
    News Release
    Medical Cannabis Innovator Khiron Continues Global Expansion as Industry Leader Throughout Europe and Latin America
  • 23
    Jun
    22
    News Release
    Khiron Announces Results of 2022 Annual General and Special Meeting
  • 2
    Jun
    22
    News Release
    Khiron Life Sciences announces pricing and size of overnight brokered offering
  • 31
    May
    22
    News Release
    Khiron to Acquire EU-GMP-Certified German Pharmaceuticals Manufacturer and Wholesaler, Expanding its European Footprint
  • 25
    May
    22
    News Release
    Khiron to Host First Quarter 2022 Conference Call on May 31, 2022
  • 10
    May
    22
    News Release
    Khiron achieves United Kingdom Cannabis Sales Volume Growth of 240% in Q1 2022
  • 2
    May
    22
    News Release
    Khiron Life Sciences Reports 2021 Fiscal Year End Results
  • 1
    May
    22
    Company Presentation
    Innovating the category of medical cannabis through improving the state of healthcare around the world
  • 27
    Apr
    22
    News Release
    Khiron to Host YE and Fourth Quarter 2021 Conference Call on May 2, 2022
  • 11
    Apr
    22
    News Release
    Global Medical Cannabis Leader Khiron Opens New Zerenia™ Clinic and Retail Pharmacy in Colombia
  • 5
    Apr
    22
    News Release
    Leading global medical cannabis company Khiron publishes clinical study on the effectiveness of its products at controlling chronic pain
  • 30
    Mar
    22
    News Release
    Medical Cannabis Innovator Khiron Continues to Disrupt Global Marketplace Signing Partnership with Teleton in Mexico
  • 7
    Mar
    22
    News Release
    Khiron Life Sciences to Present at Upcoming March Investor Conferences
  • 1
    Mar
    22
    Company Presentation
    Khiron Corporate Presentation
  • 17
    Feb
    22
    News Release
    Khiron Adds Another Clinic Location in Peru
  • 31
    Jan
    22
    News Release
    Khiron Opens New Medical Cannabis Clinic in Colombia
  • 4
    Jan
    22
    News Release
    Mandatory Insurance Coverage for Medical Cannabis Now Expands to More than 50 million Colombians
  • 9
    Dec
    21
    News Release
    Khiron to Participate in the Lytham Partners Winter 2021 Investor Conference
  • 1
    Dec
    21
    Company Presentation
    Khiron Corporate Presentation
  • 23
    Nov
    21
    News Release
    Khiron Announces Grants of Options and Restricted Share Units
  • 22
    Nov
    21
    News Release
    Khiron Reports Q3 Results – Revenue Increased 83% YoY, 26% QoQ